Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged fraud between June 2023 and June 2025. The lawsuit claims that the company made false statements regarding the safety of its gene therapy, ELEVIDYS, which is intended for treating Duchenne Muscular Dystrophy. Allegations include that severe side effects were not properly detected and that this could lead to halted trials and increased regulatory scrutiny. Investors have until August 25, 2025, to act as lead plaintiffs in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims that statements regarding the safety of ELEVIDYS were misleading.
  • Adverse events from ELEVIDYS treatment raised significant safety concerns.
  • Recruitment and dosing in ELEVIDYS trials may need to be halted due to issues.

Full Press Release Details

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Sarepta securities lawsuit about?

The lawsuit involves alleged securities fraud affecting Sarepta investors from June 22, 2023, to June 24, 2025.

What claims are made in the Sarepta lawsuit?

The lawsuit claims that Sarepta misled investors about ELEVIDYS's safety risks and trial protocols.

How can affected investors join the Sarepta lawsuit?

Affected investors can request to be lead plaintiffs by August 25, 2025, or participate without obligation.

Are there any costs to participate in the lawsuit?

There are no costs or fees for class members to participate in the lawsuit.

Who can I contact for more information on the lawsuit?

Investors can contact Joseph E. Levi, Esq., via email or phone for more details.

Last updated: Jul 17, 2025